User login
Reporting on highlights in axial spondyloarthritis (AxSpA) from the American College of Rheumatology Convergence 2022, Dr Philip Mease of Swedish Medical Center in Seattle calls attention to studies on promising therapeutic outcomes.
He begins with the late-breaking long-range therapeutic results of bimekizumab, which was shown to be effective in patients with nonradiographic AxSpA and those with ankylosing spondylitis over 52 weeks.
Next, he reports on a study examining withdrawal vs tapering of golimumab, which underscored the benefit of tapering in prevention of disease flares.
Dr Mease then discusses a study in which cycling between tumor necrosis factor inhibitors provided disappointing results in the AxSpA population, suggesting that switching to a therapy with a different mechanism of action might achieve better outcomes.
Another study cited by Dr Mease explored the use of combination therapy in patients with AxSpA, which yielded promising results. Should this approach take hold, Dr Mease says that in the future, "we'll be more like oncologists, mixing and matching and doing what's best for our patients to bring them into a state of remission."
Dr Mease closes by discussing a large study investigating COVID among patients with autoimmune diseases, including AxSpA and psoriasis. The study found that neither the conditions themselves nor their treatments significantly increased risk for severe outcomes.
--
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine; Director, Department of Rheumatology Research, Swedish Medical Center/Providence St. Joseph's Health, Seattle Rheumatology Associates, Seattle, Washington
Philip Mease, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Acelyrin; Aclaris; Amgen; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly; Galapagos; Gilead; GlaxoSmithKline; Inmagene; Janssen; MoonLake; Novartis; Pfizer; Sun Pharma; UCB
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Amgen; Eli Lilly; Janssen; Novartis; Pfizer; UCB
Received research grant from: AbbVie; Amgen; Bristol Myers Squibb; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer; Sun Pharma; UCB
Reporting on highlights in axial spondyloarthritis (AxSpA) from the American College of Rheumatology Convergence 2022, Dr Philip Mease of Swedish Medical Center in Seattle calls attention to studies on promising therapeutic outcomes.
He begins with the late-breaking long-range therapeutic results of bimekizumab, which was shown to be effective in patients with nonradiographic AxSpA and those with ankylosing spondylitis over 52 weeks.
Next, he reports on a study examining withdrawal vs tapering of golimumab, which underscored the benefit of tapering in prevention of disease flares.
Dr Mease then discusses a study in which cycling between tumor necrosis factor inhibitors provided disappointing results in the AxSpA population, suggesting that switching to a therapy with a different mechanism of action might achieve better outcomes.
Another study cited by Dr Mease explored the use of combination therapy in patients with AxSpA, which yielded promising results. Should this approach take hold, Dr Mease says that in the future, "we'll be more like oncologists, mixing and matching and doing what's best for our patients to bring them into a state of remission."
Dr Mease closes by discussing a large study investigating COVID among patients with autoimmune diseases, including AxSpA and psoriasis. The study found that neither the conditions themselves nor their treatments significantly increased risk for severe outcomes.
--
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine; Director, Department of Rheumatology Research, Swedish Medical Center/Providence St. Joseph's Health, Seattle Rheumatology Associates, Seattle, Washington
Philip Mease, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Acelyrin; Aclaris; Amgen; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly; Galapagos; Gilead; GlaxoSmithKline; Inmagene; Janssen; MoonLake; Novartis; Pfizer; Sun Pharma; UCB
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Amgen; Eli Lilly; Janssen; Novartis; Pfizer; UCB
Received research grant from: AbbVie; Amgen; Bristol Myers Squibb; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer; Sun Pharma; UCB
Reporting on highlights in axial spondyloarthritis (AxSpA) from the American College of Rheumatology Convergence 2022, Dr Philip Mease of Swedish Medical Center in Seattle calls attention to studies on promising therapeutic outcomes.
He begins with the late-breaking long-range therapeutic results of bimekizumab, which was shown to be effective in patients with nonradiographic AxSpA and those with ankylosing spondylitis over 52 weeks.
Next, he reports on a study examining withdrawal vs tapering of golimumab, which underscored the benefit of tapering in prevention of disease flares.
Dr Mease then discusses a study in which cycling between tumor necrosis factor inhibitors provided disappointing results in the AxSpA population, suggesting that switching to a therapy with a different mechanism of action might achieve better outcomes.
Another study cited by Dr Mease explored the use of combination therapy in patients with AxSpA, which yielded promising results. Should this approach take hold, Dr Mease says that in the future, "we'll be more like oncologists, mixing and matching and doing what's best for our patients to bring them into a state of remission."
Dr Mease closes by discussing a large study investigating COVID among patients with autoimmune diseases, including AxSpA and psoriasis. The study found that neither the conditions themselves nor their treatments significantly increased risk for severe outcomes.
--
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine; Director, Department of Rheumatology Research, Swedish Medical Center/Providence St. Joseph's Health, Seattle Rheumatology Associates, Seattle, Washington
Philip Mease, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: AbbVie; Acelyrin; Aclaris; Amgen; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly; Galapagos; Gilead; GlaxoSmithKline; Inmagene; Janssen; MoonLake; Novartis; Pfizer; Sun Pharma; UCB
Serve(d) as a speaker or a member of a speakers bureau for: AbbVie; Amgen; Eli Lilly; Janssen; Novartis; Pfizer; UCB
Received research grant from: AbbVie; Amgen; Bristol Myers Squibb; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer; Sun Pharma; UCB
